Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
7.5
Expiration
Dec 24, 2026
DTE
41d
Moneyness
ITM
Intrinsic
$1.49
IBRX 7.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.35 | +16.67% | 10 | 24 |
| Nov 20, 2026 | 7d | $0.48 | -7.69% | 1 | 130 |
| Nov 27, 2026 | 14d | $0.81 | +5.19% | 56 | 222 |
| Dec 4, 2026 | 21d | $1.00 | +11.11% | 2 | 1,106 |
| Dec 11, 2026 | 28d | $0.95 | +0.00% | 7 | 8 |
| Dec 24, 2026 | 41d | — | — | 0 | 4 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $1.15 | +0.88% | 14 | 22,986 |
| Jan 21, 2028 | 434d | $2.56 | +2.40% | 5 | 9,718 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.